Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.
Here's how to play the biotech with earnings on the horizon.
Current owners of the small biotech company's shares should continue to hold them based on its charts but should put in a stop, too.
India's drugmakers aim to manufacture generic versions of any coronavirus 'cure', even before the full findings as to how effective they are.
Here are my thoughts on the quarter and trading the stock.
I've followed this name before it went public, and it's got some potentially promising treatments in its pipeline.
Flexion Therapeutics and BioDelivery Sciences International have promising products that should do well once the fixation on Covid-19 treatments wanes.
This biotech is one of two companies in human trials for a vaccine for Covid-19.
CEO McMullen said it's not a matter of if they'll have a vaccine, but when.
Realty Income isn't the highest yielding REIT around, but it offers sustainable dividends, and here's why.